---

Highlights for February 2018

1. Cipla ties up with Roche to sell two key drugs Tocilizumab and Syndyma in India
2. Alkem Labs signs pact to market Stempeutics stem cell therapy for Osteoarthritis
3. Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, for Ophthalmic Solution Products
4. SMS Lifesciences to acquire API maker Mahi Drugs
5. Pieris in immuno-oncology deal with Seattle Genetics worth $1.2 Bn
6. Qiagen inks $191Mn deal to buy infection test panel firm STAT-Dx
7. Janssen Biotech andTheravance ink GI pact worth up to $1Bn 
8. Filtration Group closes acquisition of Essentra’s Porous Technologies at £220 Mn (i.e. $306.11 Mn) free of cash and debt
9. Scotland’s TCB inks CAR-T deal with Japan’s NIPRO to treat Cancer
10. Merck buys Australian I-O firm Viralytics for $394 Mn
11. Arix Bioscience has entered into a strategic agreement with Ipsen to develop and commercialize innovative therapies
12. GeneTx inks worldwide pact with Texas A&M, to develop and commercialize an antisense treatment for Angelman Syndrome

Updates at Aagami:

1. New client win:Novel Oral Contraceptive with annual sales potential of $700 Mn in US, available for Licensing/acquisition 
2. Aagami completed 15 years and looks forward to providing further value to its Internal & External stakeholders
3. Aagami completed a fruitful business trip to South Korea, Japan and India
4. A US client in Medtech sector brought to Aagami a robust EB5 opportunity for anyone who is looking to migrate to the US